Katie Derington
@PharmDerington
Followers
173
Following
755
Media
20
Statuses
378
PharmD | Researcher @UofUPHS | heart health | dog and human mom |
Denver, CO
Joined June 2019
Why do we think this is happening? What do we need to do to change it?
In >2.8 million Veterans with high BP, initiation of anti-HTN monotherapy was most common and increased over time, even if systolic BP >=160 mmHg. #AHAJournals @YizheXu6 @PharmDerington @jordy_bc @adambress @UofUPHS @UofUHSIR
https://t.co/Bnm2K0MhHI
0
2
7
New MEPS analysis shows a reduce in exclusivity for lisinopril, amlodipine and losartan to treat hypertension @JoshJPharmD @adambress @ihdezdelso @PharmDerington @AlexanderZheut1 @jordanbking @wccushman
https://t.co/F0kefGDJh8
0
2
6
Congratulations to Dr. @adambress on being named a 2024 Presidential Scholar at the U! 🎉 Recipients of this award are chosen for their leadership in their field & significant contribution to scholarship, education & outreach at @UUtah. Read more @ https://t.co/ALpNOTqOis
2
7
33
So, so proud of you @JoshJPharmD !!
Congratulations to Joshua Jacobs, 2024 New Investigator Award winner! As part of the ceremony, he will present his lecture, Gaps, Disparities, and Optimization of Pharmacotherapy in Patients with Cardiovascular Disease. #ACCPAM24
@JoshJPharmD @uofupharmacy @UofUPopHealthEd
0
1
8
Lowering SBP to <120 mm Hg in SPRINT-eligible adults in the US could ⬆️ healthcare costs by $2 billion annually (~$135 per person treated). #AHAJournals #ResearchLetter @PharmDerington @RansmondBerchie @Doctor_GT @EmilyLevitan @MonikaSafford @adambress
https://t.co/s7FIqG31wp
1
2
17
About 25% of patients initiating hypertension treatment do so with a beta blocker, the majority of whom do not have a compelling indication. This is getting better over time, but is still high in recent years
Amazing job @PharmDerington presenting our VA data showing surprisingly high use of beta-blockers as first-line antihypertensive therapy despite the absence of compelling indications @adambress #Hypertension24
0
9
20
Thank you @MM_Santisteban @CamGMcCarthy & TAC team for another 💎 networking #CHAMP lunch at #Hypertension2024 Thank you for matching me with 🌟 Mentee @PharmDerington Delighted to reunite with 🌟🌟 #WomenInSTEM Camilla @CFWenceslau Carmen @Carmendemigue12 🙌 @CouncilonHTN
1
11
36
So lucky to work with this talented group of folks!
📷 The Division of Biostatistics @UofUMedicine is building something special. Here we are at #JSM2024. We're recruiting faculty, post-docs and students. Come join us! #BiostatsElevated
@UofUBiostats
@UofUPHS
@AmstatNews
0
0
2
We (@taraichang @lama_ghazi @TimAndersonMD @k_sauser and others) are excited to publish our new AHA Scientific Statement on the management of elevated blood pressure in the inpatient setting @UofUHealth @UofUMedicine @UofUPHS @AHAScience @HyperAHA
https://t.co/nF1hgmVQ5P
ahajournals.org
Over the past 3 decades, a substantial body of high-quality evidence has guided the diagnosis and management of elevated blood pressure (BP) in the outpatient setting. In contrast, there is a lack of...
1/ 🆕Scientific Statement from the American Heart Association: The Management of Elevated Blood Pressure in the Acute Care Setting 📷 Care pathways for the management of BP in the acute care setting and transitions of care.
3
10
37
Should we rethink our approach to treating inpatient asymptomatic hypertension? The terms "hypertensive urgency" and "hypertensive crisis" might be outdated, potentially leading to inappropriate treatment. This new AHA Scientific Statement suggests it's time for a change.
1/ 🆕Scientific Statement from the American Heart Association: The Management of Elevated Blood Pressure in the Acute Care Setting 📷 Care pathways for the management of BP in the acute care setting and transitions of care.
1
3
6
Amazing @ACCinTouch #ACC24 session “unleashing power of tech for IHD” ❤️Tremendous power for AI to assist clinical team ❤️Can’t let tech worsen #digitaldivide, use it to improve #healthequity ❤️Must address #pharamcoequity. Let’s partner w @PhRMA on solutions.
0
3
13
Surprised to see losartan topping this list. When starting an ARB, losartan is the last option I'd go with, for one simple reason. 🧵 /1
What is your go to ARB for HTN? Do you have one? Why choose one over the other?
30
195
851
Very excited to officially start my new position @JAHA_AHA Early Career Editorial Board among this wonderful group of talented people! Looking forward to an enriching experience full of learning and meaningful contributions to science! @AHAScience @CircAHA
https://t.co/jRcMmIALpr
8
5
70
Great new work from @JoshJPharmD !!
In the SPRINT trial, self-reported medication adherence was not a key driver of therapeutic inertia in patients above goal. #AHAJournals @JoshJPharmD @PharmDerington @AlexanderZheut1 @jordy_bc @johnbu08 @Ian_Kronish @Daniel_Addo_ @adambress @UofUPHS
https://t.co/QlmZsTEP0Y
0
1
7
So proud of @JJChipman, @PharmDerington, @drdustijones, & Dr. Yizhen Xu on their acceptance in the 2024-2025 #VPCAT Scholar Program! @UofUBiostats
@UofUHSIR
@UofUCPS
0
5
14
Great work by @UofUHealth pharmacist and PhD student Josh Jacobs presenting data on inpatient diuretic use. Quickly becoming a ⭐️ in HF research
1
5
34
In this @Health_Affairs Forefront article, we discuss the potential policy implications of public detachment and desensitization to firearm violence, as well as evidence and recommendations for policy researchers, media, and clinicians. 👇
In their new Forefront article, @evangoldstein + @lauracprater of @UUtah + @UW discuss how firearm violence in the US + the endless stream of media coverage about firearm violence may be fatiguing the US public to remain politically activated. #GunControl
0
4
10
@ACCP really needs to rethink this. I can’t understand for the life of me why you would give someone like this a platform. Please do better!
0
1
18
Our department is dedicated to conducting research that promotes health equity for all individuals. Check out our PhD student spotlight on @Daniel_Addo_ & @JoshJPharmD @ https://t.co/mNO9xLU68Y
@UofUPopHealthEd
@uofuedi
@UofUHealth
#healthequity #healthdisparities #phdlife
0
5
12
HF Won’t Wait! Delay ARNI ➡️ 42% ⬆️ risk CV☠️/HF🏨 Delay BB ➡️ 25% ⬆️ risk ☠️ Delay MRA ➡️ 37% ⬆️ risk CV☠️/HF🏨 Delay SGLTi ➡️ 58% ⬆️ risk CV☠️/HF🏨/ER Unnecessary delays in any one or more of foundational GDMT ➡️ preventable ☠️/🏨 Urgency and intensity needed
6
108
280